Nomura Holdings’s Orchestra BioMed OBIO Stock Holding History

Nomura Holdings’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-20,502	Closed	-$205K	–	1891
2022 Q2	$205K	Hold	20,502	–	–	﹤0.01%	1282
2022 Q1	$204K	Hold	20,502	–	–	﹤0.01%	1574
2021 Q4	$204K	Buy	20,502 +5,000	+32%	+$49.3K	﹤0.01%	1829
2021 Q3	$152K	Hold	15,502	–	–	﹤0.01%	1733
2021 Q2	$157K	Sell	15,502 -9,498	-38%	-$98.3K	﹤0.01%	1776
2021 Q1	$276K	Buy	+25,000	New	+$304K	﹤0.01%	1533

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Nomura Holdings's OBIO Position: Q3 2022 in Review

Nomura Holdings sold out of Orchestra BioMed (OBIO) in Q3 2022, closing a stake of 20,502 shares — an estimated $205K sold.

Nomura Holdings first reported a position in OBIO in Q1 2021 and held it in 6 quarters. The position peaked at $276K in Q1 2021. 23 funds tracked by Wall St. Rank hold OBIO as of Q3 2022.

Nomura Holdings reported no remaining Orchestra BioMed position as of Q3 2022 after selling out during the quarter.
Nomura Holdings sold 20,502 Orchestra BioMed shares in Q3 2022, an estimated $205K.
Nomura Holdings first reported a position in Orchestra BioMed in Q1 2021 and held it in 6 quarters.
Nomura Holdings's Orchestra BioMed position peaked at $276K in Q1 2021.
23 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2022.

Based on Nomura Holdings's 13F filing for Q3 2022, filed 15 Nov 2022.